Imunon, Inc. (IMNN) grants chair 6,358 shares instead of cash salary

Rhea-AI Filing Summary

Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. granted its Executive Chairman Michael H. Tardugno 6,358 shares of common stock on July 31, 2026, valued at $1.59 per share, as stock in lieu of cash base salary, increasing his direct holdings to 75,357 shares plus 4,622 shares held indirectly through an IRA.

Insider Trade Summary

Net Buyer: 6,358 shares

Net Buy 2 txns

Insider Tardugno Michael H

Role Executive Chairman of Board

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	6,358	$1.59	$10K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 75,357 shares (Direct); Common Stock — 4,622 shares (Indirect, Held by IRA)

Footnotes (1)

1. F1. Stock granted in lieu of cash for base salary

Key Figures

Shares granted: 6,358 shares Grant valuation: $1.59 per share Direct holdings after grant: 75,357 shares +2 more

5 metrics

Shares granted 6,358 shares Common stock granted to Executive Chairman on July 31, 2026

Grant valuation $1.59 per share Value per share for stock granted in lieu of cash base salary

Direct holdings after grant 75,357 shares Total directly held Imunon common shares following the award

Indirect IRA holdings 4,622 shares Imunon common shares reported as held indirectly by IRA

Equity compensation events 1 acquisition One grant, award, or other acquisition reported in the period

Key Terms

Grant, award, or other acquisition, Held by IRA, stock granted in lieu of cash for base salary

3 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Held by IRA financial

"nature_of_ownership: Held by IRA"

stock granted in lieu of cash for base salary financial

"Footnote: Stock granted in lieu of cash for base salary"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 04:13 PM Accepted by SEC EDGAR 08/04/2026 - 04:12 PM Learn about SEC filing dates

FAQ

What insider stock transaction did Imunon (IMNN) report for Michael H. Tardugno?

Imunon reported that Executive Chairman Michael H. Tardugno received 6,358 shares of common stock on July 31, 2026, as a grant. The shares were issued in lieu of cash base salary, reflecting a form of equity-based executive compensation.

How many Imunon (IMNN) shares did Michael H. Tardugno receive and at what value?

Michael H. Tardugno was granted 6,358 shares of Imunon common stock, valued at $1.59 per share. According to the disclosure, the stock grant served as compensation in place of cash for his base salary.

What are Michael H. Tardugno’s total Imunon (IMNN) shareholdings after the reported grant?

Following the grant, Michael H. Tardugno directly holds 75,357 shares of Imunon common stock. He also reports 4,622 additional shares held indirectly through an IRA, reflecting both direct and indirect ownership positions.

How was the Imunon (IMNN) stock grant to Michael H. Tardugno structured?

The stock grant to Michael H. Tardugno consisted of 6,358 shares of common stock provided in lieu of cash for base salary. This indicates that part of his executive compensation was paid in equity rather than in cash.

Does Michael H. Tardugno hold any Imunon (IMNN) shares indirectly?

Yes. In addition to his direct holdings, Michael H. Tardugno reports 4,622 Imunon shares held indirectly, noted as “Held by IRA”. This reflects ownership through an individual retirement account rather than directly in his own name.

Was the Imunon (IMNN) stock grant to Michael H. Tardugno made under a Rule 10b5-1 trading plan?

No. The disclosure indicates the Rule 10b5-1 checkbox was not marked as affirmative. The reported grant of 6,358 shares in lieu of cash salary is therefore not identified as being executed under a pre-arranged trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tardugno Michael H

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman of Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2026		A		6,358(1)	A	$1.59	75,357	D
Common Stock								4,622	I	Held by IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for base salary

	/s/ Susan Eylward, Attorney-in-Fact for Michael Tardugno	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)